[Atazanavir/cobicistat (Evotaz®) in HIV infection]

González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001394
Original Title: Atazanavir/cobicistat (Evotaz®) en infección por VIH
Authors' recommendations: CONCLUSIONS High quality evidence shows that in patients with HIV-1 infection the use of tenofovir plus emtricitabine in combination with fixed doses of atazanavir/cobicistat did not prove to be inferior to its use associated to atazanavir plus ritonavir; outcome was the rate of patients reaching an undetectable viral load (less than 50 copies/mL) at Week 48 and maintaining the response at Week 144. The adverse event profile and treatment discontinuation due to AE were similar. The clinical practice guidelines consider it among the valid treatment alternatives but it is not among the preferred schemes to be used in patients with HIV-1 infection. In high-income countries, it is covered by public and private health sponsors, while in Latin American countries it is not.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • HIV
  • HIV Infections
  • Atazanavir Sulfate
  • Cobicistat
  • Drug Therapy, Combination
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.